CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 479 enrolled
Drug / intervention
Hydroxychloroquine +1 moredrug
Likely dose
Hydroxychloroquine 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04332991
NCT04332991Phase 3Completed
CompareCT.gov

Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease

Massachusetts General Hospital·interventional·Posted Apr 3, 2020·Updated Mar 17, 2021

In Brief

A Phase 3 clinical trial evaluating Hydroxychloroquine and Placebo for Coronavirus and 2 related conditions. Completed, enrolled 479 participants across 40 sites.

Detailed Summary

ORCHID is a multicenter, blinded, placebo-controlled, randomized clinical trial evaluating hydroxychloroquine for the treatment of adults hospitalized with COVID-19. Patients, treating clinicians, and study personnel will all be blinded to study group assignment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronavirus, Acute Respiratory Infection, SARS-CoV Infection
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedApr 3, 2020
Enrollment StartApr 2, 2020
Primary CompletionJun 19, 2020
Study CompletionJul 23, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.2 years ago

Interventions

Hydroxychloroquinedrug

Hydroxychloroquine is available in 200 mg oral tablets of hydroxychloroquine sulfate. For this COVID-19 trial, we will use an oral or enteral dose of hydroxychloroquine 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.

Placebodrug

Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.